SAGE Sage Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

SAGE [NASD]

Sage Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-11.80	Insider Own	0.10%	Shs Outstand	51.93M	Perf Week	9.60%
Market Cap	3.50B	Forward P/E	-	EPS next Y	-9.54	Insider Trans	0.00%	Shs Float	51.00M	Perf Month	17.02%
Income	-611.70M	PEG	-	EPS next Q	-2.39	Inst Own	-	Short Float	12.18%	Perf Quarter	47.98%
Sales	8.90M	P/S	393.18	EPS this Y	-65.50%	Inst Trans	0.04%	Short Ratio	9.28	Perf Half Y	96.99%
Book/sh	14.25	P/B	4.92	EPS next Y	4.20%	ROA	-60.30%	Target Price	79.05	Perf Year	-50.27%
Cash/sh	15.15	P/C	4.63	EPS next 5Y	13.10%	ROE	-67.70%	52W Range	25.01 - 155.33	Perf YTD	-2.94%
Dividend	-	P/FCF	-	EPS past 5Y	-51.60%	ROI	-75.00%	52W High	-54.89%	Beta	2.47
Dividend %	-	Quick Ratio	12.20	Sales past 5Y	-	Gross Margin	92.90%	52W Low	180.17%	ATR	3.15
Employees	675	Current Ratio	12.20	Sales Q/Q	22.20%	Oper. Margin	-	RSI (14)	67.52	Volatility	5.42% 5.05%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	20.00%	Profit Margin	-	Rel Volume	0.86	Prev Close	69.72
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 AMC	Payout	-	Avg Volume	668.82K	Price	70.07
Recom	1.90	SMA20	11.52%	SMA50	23.06%	SMA200	42.88%	Volume	573,861	Change	0.50%

Sep-11-20

Upgrade

Wedbush

Neutral → Outperform

Aug-10-20

Upgrade

Raymond James

Mkt Perform → Outperform

$70

May-08-20

Downgrade

Wedbush

Outperform → Neutral

Apr-08-20

Downgrade

Guggenheim

Buy → Neutral

Mar-18-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$73 → $60

Mar-06-20

Initiated

Citigroup

Buy

$71

Feb-28-20

Reiterated

H.C. Wainwright

Neutral

$87 → $78

Feb-06-20

Initiated

Mizuho

Neutral

Dec-06-19

Reiterated

RBC Capital Mkts

Outperform

$190 → $100

Dec-05-19

Reiterated

Guggenheim

Buy

$200 → $110

Dec-05-19

Downgrade

SunTrust

Buy → Hold

Oct-30-19

Initiated

H.C. Wainwright

Neutral

$160

May-23-19

Initiated

Wedbush

Outperform

Apr-25-19

Initiated

Jefferies

Buy

$195

Dec-14-18

Initiated

Wolfe Research

Outperform

Oct-11-18

Initiated

Oppenheimer

Outperform

$170

Aug-07-18

Reiterated

Stifel

Buy

$198 → $239

Aug-06-18

Initiated

Piper Jaffray

Overweight

$206

Jun-06-18

Initiated

Ladenburg Thalmann

Buy

$230

Mar-26-18

Resumed

Canaccord Genuity

Buy

$210

Oct-19-20 05:00PM	Sage Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 Business Wire
Oct-15-20 06:30AM	Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD Business Wire
Oct-01-20 07:00AM	Sage Therapeutics Appoints Barry Greene to Board of Directors Business Wire
Sep-16-20 04:55PM	SAGE Therapeutics Inc (SAGE): Hedge Funds In Wait-and-See Mode Insider Monkey
Sep-15-20 09:56AM	Sage Therapeutics (NASDAQ:SAGE) Share Prices Have Dropped 65% In The Last Year Simply Wall St.
Sep-11-20 01:38PM	Sage Therapeutics Upgraded on Potential for Depression Drug TheStreet.com
09:38AM	Benzinga's Top Upgrades, Downgrades For September 11, 2020 Benzinga
08:41AM	Sage Therapeutics (SAGE) in Focus: Stock Moves 5.1% Higher Zacks
Sep-10-20 06:30AM	Sage Therapeutics FutureCast to Provide Update on Pipeline Progression and Additional Insights into Potential of Brain Health Franchises Business Wire +5.14%
Sep-01-20 06:30AM	Sage Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Aug-20-20 04:31PM	Sage Therapeutics to Host Sage FutureCast Webcast Business Wire
Aug-10-20 05:31PM	Sage Therapeutics Inc (SAGE) Q2 2020 Earnings Call Transcript Motley Fool +5.15%
07:20AM	Recap: Sage Therapeutics Q2 Earnings Benzinga
07:01AM	Have Insiders Been Buying Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares? Simply Wall St.
06:30AM	Sage Therapeutics Announces Second Quarter 2020 Financial Results and Highlights Pipeline and Business Progress Business Wire
Jul-30-20 06:30AM	Sage Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire
Jul-21-20 06:30AM	Sage Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020 Business Wire
Jul-13-20 10:22AM	Did Hedge Funds Make The Right Call On SAGE Therapeutics Inc (SAGE) ? Insider Monkey
Jun-24-20 03:58PM	Edited Transcript of SAGE earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-17-20 04:04PM	Neurocrine Adds to Pipeline With $2 Billion Takeda Deal GuruFocus.com
Jun-10-20 08:37PM	Should You Avoid SAGE Therapeutics Inc (SAGE)? Insider Monkey
Jun-09-20 09:55AM	Is There Any Hope Left for Sage Therapeutics? Motley Fool
Jun-01-20 06:30AM	Sage Therapeutics to Present at Goldman Sachs 41st Annual Global Healthcare Conference Business Wire
May-09-20 05:01PM	Sage Therapeutics Inc (SAGE) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 06:30AM	Sage Therapeutics to Present at Bank of America Health Care Conference 2020 Business Wire
May-07-20 04:01PM	Sage Therapeutics Announces First Quarter 2020 Financial Results and Highlights Pipeline and Business Progress Business Wire
May-03-20 07:30PM	One Biotech Stock For 2020 Oilprice.com
Apr-22-20 11:09AM	The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics Zacks
Apr-21-20 07:39AM	Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results Zacks
Apr-20-20 07:48AM	Sage Therapeutics' Shares March Higher, Can It Continue? Zacks +10.60%
Apr-16-20 06:30AM	Sage Therapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020 Business Wire
Apr-13-20 10:51AM	How Sage Therapeutics (SAGE) Stock Stands Out in a Strong Industry Zacks
Apr-08-20 12:29PM	Sage Therapeutics Slash Staff by Half TheStreet.com
10:47AM	Sage Therapeutics Lays Off Staff to Save Cash After Failed Drug Trial Barrons.com
07:53AM	Sage to restructure, let go of 340 workers MarketWatch
06:10AM	Sage slashes 53% of staff as hospitals cut inpatient stays American City Business Journals
06:09AM	Here are Mass. companies that have laid off or furloughed workers American City Business Journals
04:34AM	SAGE Announces Massive Restructuring To Focus On Failed Depression Drug SmarterAnalyst
Apr-07-20 04:01PM	Sage Therapeutics Announces Restructuring to Advance Corporate Strategy and Pipeline Business Wire
08:37AM	Sage Therapeutics (SAGE) in Focus: Stock Moves 9.3% Higher Zacks
Apr-03-20 04:30PM	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-27-20 02:53PM	Hedge Funds Were Buying SAGE Therapeutics Inc (SAGE) Before The Coronavirus Insider Monkey
Mar-20-20 08:30PM	An Egg Stock That Looks Tasty, Especially Now Barrons.com -5.64%
Mar-19-20 06:57PM	Edited Transcript of SAGE earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Mar-18-20 06:30AM	Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration Business Wire
Mar-12-20 08:45AM	Why Sage Therapeutics (SAGE) Stock Might be a Great Pick Zacks -17.99%
Mar-11-20 07:00AM	Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano GlobeNewswire -8.62%
Mar-04-20 04:30PM	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-02-20 09:59AM	Sage Therapeutics Stock Is a Steal, Analyst Says Barrons.com +13.53%
07:24AM	Sage Therapeutics, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
Feb-27-20 07:39PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud GlobeNewswire -18.29%
06:30AM	Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress Business Wire
Feb-26-20 08:31AM	Why Earnings Season Could Be Great for Sage Therapeutics (SAGE) Zacks
Feb-25-20 12:03PM	The Sage Therapeutics (NASDAQ:SAGE) Share Price Is Up -56% And Shareholders Are Holding On Simply Wall St.
Feb-24-20 06:30AM	Sage Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference Business Wire
Feb-10-20 06:30AM	Sage Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 Business Wire
Feb-04-20 04:30PM	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Feb-03-20 11:27AM	Andreas Halvorsen Trims Adaptive Biotechnologies Stake GuruFocus.com
Jan-17-20 08:40AM	An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 30% Undervalued Simply Wall St.
Jan-09-20 08:44AM	Hedge Fund Favorites vs. SAGE Therapeutics Inc (SAGE) In 2019 Insider Monkey
Jan-03-20 04:30PM	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Dec-29-19 03:24AM	Corporate Insiders Pull the Trigger on 3 Buy-Rated Stocks TipRanks
Dec-23-19 02:47PM	Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch
06:30AM	Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020 Business Wire
Dec-19-19 03:07PM	Minerva shares fall on failed depression drug trial MarketWatch
Dec-16-19 11:28AM	Weekly CEO Buys Highlight GuruFocus.com
Dec-14-19 02:56PM	Notable Insider Buys In The Past Week: Enterprise Products Partners, PBF Energy, Sage Therapeutics Benzinga
Dec-12-19 08:15PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened ACCESSWIRE +5.71%
10:38AM	Trade Alert: The Chief Scientific Officer Of Sage Therapeutics, Inc. (NASDAQ:SAGE), Albert Robichaud, Has Just Spent US$1.6m Buying Shares Simply Wall St.
Dec-11-19 08:01PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened GlobeNewswire +8.50%
09:41AM	Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks
Dec-10-19 09:18PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened PR Newswire
07:30AM	Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP) Business Wire
Dec-09-19 10:20AM	Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher Zacks
06:20AM	SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders ACCESSWIRE
Dec-06-19 03:00PM	Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment Benzinga +7.11%
09:30AM	Sage Therapeutics Stock Collapsed After Depression-Drug Results. Analysts Say It Has Lost Enough Ground. Barrons.com
09:26AM	Sage Therapeutics' Depression Drug Fails in Study, Stock Down Zacks
Dec-05-19 08:31PM	Lost Money in Sage Therapeutics, Inc.? Business Wire -59.67%
04:18PM	6 Underperforming Stocks in Gurus' Portfolios GuruFocus.com
04:05PM	This Biotech Collapsed 60% After Its Depression Drug Unexpectedly Failed Investor's Business Daily
11:00AM	Sage Shareholders Face Classic Biotech Investor Dilemma Bloomberg
10:24AM	Sage Therapeutics Stock Is Cratering Because Its Depression Treatment Failed in a Key Trial Barrons.com
09:54AM	Shares of Cambridge biotech plunge as depression drug fails late-stage trial American City Business Journals
09:42AM	Sage Plunges as Key Depression Study Fails to Show Benefit Bloomberg
07:21AM	UPDATE 1-Sage's oral depression therapy fails in late-stage trial; shares plunge Reuters
07:18AM	Sage Therapeutics's stock plunges after depression treatment study fails primary endpoint MarketWatch
06:40AM	Sage's oral depression therapy fails in late-stage trial Reuters
06:30AM	Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder Business Wire
Dec-04-19 09:28AM	Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy ? Insider Monkey
Dec-03-19 04:30PM	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
09:57AM	Edited Transcript of SAGE earnings conference call or presentation 12-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-25-19 06:44PM	Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders Business Wire
Nov-20-19 06:10PM	These 3 Strong Buy Healthcare Stocks Have 40% Upside Or More, Says Cowen TipRanks
Nov-15-19 10:02AM	VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints Zacks
Nov-12-19 06:31AM	Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress Business Wire
Nov-11-19 04:30PM	Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference Business Wire
07:50AM	5 Biotech Stocks Set to Beat Q3 Earnings Estimates Zacks
Nov-05-19 06:00PM	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
12:01PM	Is Sage Therapeutics, Inc.'s (NASDAQ:SAGE) CEO Salary Justified? Simply Wall St.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
IGUCHI KIMI	CFO & Treasurer	Apr 30	Option Exercise	1.36	4,000	5,440	33,261	May 04 04:53 PM
IGUCHI KIMI	CFO & Treasurer	Dec 10	Option Exercise	1.36	500	680	29,261	Dec 10 09:26 PM
Robichaud Albert	Chief Scientific Officer	Dec 09	Option Exercise	20.12	15,743	316,746	111,400	Dec 10 08:04 PM
IGUCHI KIMI	CFO & Treasurer	Dec 09	Option Exercise	1.36	15,000	20,400	28,761	Dec 10 09:26 PM
JONAS JEFFREY M	President & CEO	Dec 09	Buy	64.20	7,500	481,500	54,530	Dec 10 08:04 PM
Robichaud Albert	Chief Scientific Officer	Dec 09	Buy	64.16	25,000	1,604,000	136,400	Dec 10 08:04 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience